Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Jackson

Otolaryngology Saint Louis, MO Medical Doctor

NPI 1710114582 CMS profile 1280970

4921 Parkview Pl, Dept Otolaryngology, Ste 11A, Saint Louis, MO 63110

Open in the dashboard

General payments

$284,204

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Jackson of Saint Louis, MO is reported in the CMS Open Payments database as having received $284,204 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,026 31
2024 General $28,087 17
2023 General $16,278 21
2022 General $40,758 33
2021 General $86,901 91
2020 General $63,187 104
2019 General $1,967 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Jackson
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Ryan Jackson were reported at $47,026. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Ryan Jackson Otolaryngology median Middle half National median
2019 $1,967 $194 $82–$512 $163
2020 $63,187 $118 $42–$280 $114
2021 $86,901 $167 $63–$444 $132
2022 $40,758 $216 $84–$545 $149
2023 $16,278 $235 $93–$588 $160
2024 $28,087 $280 $111–$699 $164
2025 $47,026 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $282,484 296 payments
  2. Inspire Medical Systems, Inc. $1,476 9 payments
  3. Regeneron Healthcare Solutions, Inc. $115 1 payment
  4. Galderma Laboratories, L.P. $44 2 payments
  5. Lilly USA, LLC $32 2 payments
  6. Novartis Pharmaceuticals Corporation $22 1 payment
  7. Olympus America Inc. $18 1 payment
  8. Sun Pharmaceutical Industries Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $227,000 98 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,800 13 payments
  3. Travel and Lodging $19,325 115 payments
  4. Food and Beverage $8,079 87 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $275,334 293 payments
  2. DA VINCI SP $7,150 3 payments
  3. Inspire Upper Airway Stimulation System $1,140 3 payments
  4. INSPIRE $336 6 payments
  5. DUPIXENT $115 1 payment
  6. TALTZ $32 2 payments
  7. NEMLUVIO $26 1 payment
  8. COSENTYX $22 1 payment
  9. SOOLANTRA $18 1 payment
  10. EPIDUO FORTE $18 1 payment
  11. Other $31 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

81

Median for Otolaryngology: 297

Drug cost

$705

Median for Otolaryngology: $6,314

Branded share of claims

30.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 25 $489
Oxycodone Hcl Generic 17 $78
Levothyroxine Sodium Generic 11 $66
Chlorhexidine Gluconate Generic 15 $50
Prednisone Generic 13 $23

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$131,895

Medicare's payments for the services billed

Medicare patients

276

Average age 73

Services billed

730

114 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 35%
Depression 26%
Diabetes 25%
Cancer 24%
Chronic kidney disease 22%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record